Pfizer's Xeljanz Is First JAK Positive In PsA But Challenges Ahead

Pfizer’s oral JAK inhibitor Xeljanz is set to lead the JAK inhibitors to market in psoriatic arthritis following positive Phase III data particularly in joint inflammation, but skin findings were disappointing.